Wednesday, July 8, 2026

pharma · Opioid Use Disorder · Opioid Dependence

Indivior Pty

Indivior Pty clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

., Richmond, VA, US HQ
967 Employees
TGA registrant Type
Company details
Status
Public
HQ
., Richmond, VA, US
Employees
967
Programs
39
Drugs
19
Patents
34
Intelligence · Clinical Programs

Indivior Pty projects

13 ClinicalTrials.gov programs sponsored by Indivior Pty.

Indivior Pty has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 2.0mg Buprenorphine/0.5mg Naloxone

    Indivior Pty Ltd

    Hepatic Failure

    approved small molecule completed

    1 trial
  2. Buprenorphine (Subutex)

    Indivior Pty Ltd

    Opioid Dependency

    approved small molecule completed

    1 trial
  3. Buprenorphine + naloxone (Suboxone)

    Indivior Pty Ltd

    Opiate Dependence

    approved small molecule completed

    1 trial
  4. Buprenorphine Extended-Release Injection

    Indivior Pty Ltd

    Opioid Use Disorder

    approved small molecule completed

    1 trial
  5. INDV-6000-406

    Indivior Pty Ltd

    Opioid Use Disorder

    approved small molecule active

    1 trial
  6. P04843

    Indivior Pty Ltd

    Opiate Dependence

    approved small molecule completed

    1 trial
  7. PERSERIS

    Indivior Pty Ltd

    Schizophrenia

    approved small molecule completed

    1 trial
  8. Sublocade

    Indivior Pty Ltd

    Opioid Use Disorder, Severe

    approved small molecule completed

    1 trial
  9. Suboxone Sublingual Film

    Indivior Pty Ltd

    Opioid Dependence

    approved small molecule completed

    1 trial
  10. TM buprenorphine

    Indivior Pty Ltd

    Opioid-use Disorder

    approved small molecule completed

    1 trial
  11. Transmucosal Buprenorphine

    Indivior Pty Ltd

    Moderate to Severe Opioid-use Disorder

    approved small molecule completed

    1 trial
  12. buprenorphine

    Indivior Pty Ltd

    Hepatitis C, Chronic

    approved small molecule terminated

    1 trial
  13. buprenorphine

    Indivior Pty Ltd

    Opiate-related Disorders

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Indivior Pty have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.